Genedata and Boehringer Ingelheim Co-Develop Innovative Request Management System to Increase Biotherapeutics R&D Operational Efficiency
Fully integrated request and task management system simplifies and streamlines biologics R&D workflows and resource planning
February 20, 2018
Genedata, a leading provider of advanced software solutions for biopharmaceutical R&D, today announced the successful completion of a collaboration with Boehringer Ingelheim to develop a new Request Management System (RMS) to efficiently manage each step in the biotherapeutic protein production & QC process within R&D and simultaneously monitor all R&D operations. The system tracks the full lifecycle of task scheduling and enables real-time monitoring of the progression of requests. The RMS is particularly valuable in a division-of-labor organization in which completion of experiments requires close interaction between expression, purification, analytics, assay and other teams, and tasks performed by CROs and other external collaborators also need to be integrated.
“We could not find a suitable request management solution on the market that could handle the inherent complexity of biotherapeutics R&D workflows, so we decided to co-develop a system with Genedata,” said Dr. Miguel Teodoro, Head of IT Research at Boehringer Ingelheim. “The new Request Management System has made our overall biologics R&D process much more efficient – intergroup communication is now standardized, streamlined and traceable, and there is much less ad hoc communication. Adoption was extremely smooth and our end-users say that the new system is very intuitive.”
The new RMS has been successfully rolled out across Boehringer Ingelheim`s biotherapeutics discovery teams in the US and Europe to streamline the production and characterization of both therapeutic antibodies as well as novel bispecific and other next-generation biologics. These teams work in a geographically distributed, division-of-labor environment, within various specialized groups. They use the RMS to prioritize, schedule and fulfill complex iterative, multi-step requests, communicate status updates for each task and to ensure all steps are completed on time. The RMS is also used for managing the generation and testing of protein reagents and is fully integrated with the Genedata Biologics® platform in use at Boehringer Ingelheim.
“We are very pleased with the outcome of this collaboration with Boehringer Ingelheim, a global leader in the biopharmaceutical industry,” said Dr. Othmar Pfannes, CEO of Genedata. “Our Request Management System makes complex request fulfillment processes more efficient and optimizes resource allocation to increase productivity. This is another example of how Genedata’s infrastructure solutions harmonize and simplify critical workflows in biopharmaceutical R&D.”
Genedata plans to productize the Request Management System and make it available to other biopharma R&D organizations later this year.
For more information please contact email@example.com.
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.